While Merck Co’s drug, Januvia, has been making headlines for its possible connection to cases of acute pancreatitis, Market Watch reports that European Union regulators have approved a new drug in the same class of DPP-4 inhibitors.  Astra Zeneca PLC and Bristol-Myers Squibb Co’s drug, Onglyza, also known as saxagliptin, was approved by US regulators earlier this year.  Onglyza is a once a day pill that treats Type 2 diabetes.  It is approved for use in combination with metformin, sulphonylurea, or thiazolidinedione, when those drugs on their own are not effective in improving blood glucose levels.

cross-posted on The Faster Times